Lannett Company Profile (NYSE:LCI)

About Lannett

Lannett logoLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: LCI
  • CUSIP: 51601210
Key Metrics:
  • Previous Close: $21.50
  • 50 Day Moving Average: $28.24
  • 200 Day Moving Average: $25.91
  • 52-Week Range: $16.91 - $49.44
  • Trailing P/E Ratio: 17.92
  • Foreward P/E Ratio: 5.96
  • P/E Growth: 0.37
  • Market Cap: $793.18M
  • Outstanding Shares: 36,892,000
  • Beta: 1.93
  • Net Margins: 7.91%
  • Return on Equity: 23.75%
  • Return on Assets: 8.80%
  • Debt-to-Equity Ratio: 1.59%
  • Current Ratio: 2.00%
  • Quick Ratio: 1.62%
Additional Links:
Companies Related to Lannett:

Analyst Ratings

Consensus Ratings for Lannett (NYSE:LCI) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $29.92 (39.15% upside)

Analysts' Ratings History for Lannett (NYSE:LCI)
DateFirmActionRatingPrice TargetDetails
10/18/2016Deutsche Bank AGReiterated RatingHold$32.00 -> $26.00View Rating Details
8/24/2016Raymond James Financial Inc.Boost Price TargetOutperform$31.00 -> $43.00View Rating Details
7/12/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
3/25/2016SusquehannaLower Price Target$37.00 -> $30.00View Rating Details
3/25/2016Craig HallumLower Price TargetBuy$35.00View Rating Details
3/24/2016Roth CapitalLower Price TargetBuy$30.00 -> $27.50View Rating Details
3/24/2016Canaccord GenuityDowngradeBuy -> Sell$28.00 -> $18.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Lannett (NYSE:LCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/23/2016Q416$0.59$0.73$161.55 million$168.90 millionViewListenView Earnings Details
5/3/2016Q316$0.63$0.75$160.49 million$163.70 millionViewN/AView Earnings Details
2/3/2016Q216$0.94$0.95$141.62 million$127.06 millionViewN/AView Earnings Details
11/4/2015Q116$0.89$0.99$103.90 million$106.40 millionViewN/AView Earnings Details
8/25/2015Q415$0.86$0.91$99.30 millionViewListenView Earnings Details
5/6/2015Q315$0.94$0.97$101.10 million$99.40 millionViewN/AView Earnings Details
2/4/2015Q215$1.06$1.21$102.95 million$114.80 millionViewN/AView Earnings Details
11/3/2014Q115$0.79$0.94$91.40 million$93.40 millionViewN/AView Earnings Details
8/27/2014Q414$0.54$0.64$79.50 million$80.60 millionViewN/AView Earnings Details
5/7/2014Q314$0.60$0.63$84.50 million$80.00 millionViewN/AView Earnings Details
2/6/2014Q214$0.39$0.46$62.21 million$67.30 millionViewN/AView Earnings Details
11/7/2013Q114$0.13$0.22$41.14 million$45.82 millionViewN/AView Earnings Details
9/10/2013Q4 2013$0.07$0.12$37.89 million$40.20 millionViewN/AView Earnings Details
5/8/2013Q3 2013$0.13$0.14$35.14 million$39.00 millionViewN/AView Earnings Details
2/7/2013Q2 2013$0.05$0.10$33.53 million$36.60 millionViewN/AView Earnings Details
11/8/2012Q113$0.05$0.07$33.76 million$35.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Lannett (NYSE:LCI)
Current Year EPS Consensus Estimate: $3.39 EPS
Next Year EPS Consensus Estimate: $3.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$0.60$0.91$0.77
Q2 20167$0.62$1.10$0.93
Q4 20163$0.59$0.60$0.60
Q1 20173$0.65$0.73$0.69
Q2 20173$0.80$0.88$0.85
Q3 20173$0.88$0.92$0.90
Q4 20173$0.90$0.95$0.93
(Data provided by Zacks Investment Research)


Dividend History for Lannett (NYSE:LCI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Lannett (NYSE:LCI)
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 78.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016G. Michael LandisInsiderSell4,334$32.30$139,988.20View SEC Filing  
9/1/2016James M MaherDirectorSell1,478$33.91$50,118.98View SEC Filing  
8/31/2016G. Michael LandisInsiderSell6,786$33.41$226,720.26View SEC Filing  
6/23/2016Robert EhlingerVPSell37,141$25.06$930,753.46View SEC Filing  
6/20/2016Robert EhlingerVPSell62,859$25.40$1,596,618.60View SEC Filing  
3/1/2016Robert EhlingerVPSell69,247$25.41$1,759,566.27View SEC Filing  
2/5/2016Arthur P BedrosianCEOBuy4,500$24.91$112,095.00View SEC Filing  
2/5/2016David A DrabikDirectorBuy1,277$24.74$31,592.98View SEC Filing  
2/5/2016Kevin SmithVPBuy1,500$24.75$37,125.00View SEC Filing  
2/5/2016Martin P GalvanCFOBuy3,000$24.65$73,950.00View SEC Filing  
9/15/2015Arthur P BedrosianCEOSell5,000$55.64$278,200.00View SEC Filing  
9/8/2015John AbtVPBuy1,000$54.77$54,770.00View SEC Filing  
8/17/2015Arthur P BedrosianCEOSell5,000$52.81$264,050.00View SEC Filing  
7/15/2015Arthur P BedrosianCEOSell5,000$61.92$309,600.00View SEC Filing  
6/15/2015Arthur P BedrosianCEOSell5,000$56.31$281,550.00View SEC Filing  
5/15/2015Arthur P BedrosianCEOSell5,000$53.27$266,350.00View SEC Filing  
4/15/2015Arthur P BedrosianCEOSell5,000$69.43$347,150.00View SEC Filing  
3/16/2015Arthur P BedrosianCEOSell5,000$65.23$326,150.00View SEC Filing  
3/16/2015William SchreckCOOSell134,635$64.99$8,749,928.65View SEC Filing  
3/6/2015William SchreckCOOSell50,000$63.35$3,167,500.00View SEC Filing  
2/18/2015David A DrabikDirectorSell12,500$61.55$769,375.00View SEC Filing  
2/17/2015Arthur P BedrosianCEOSell5,000$59.89$299,450.00View SEC Filing  
2/17/2015G. Michael LandisInsiderSell11,500$58.60$673,900.00View SEC Filing  
2/13/2015Jeffrey FarberDirectorSell35,000$58.18$2,036,300.00View SEC Filing  
2/11/2015Kevin SmithVPSell109,436$56.51$6,184,228.36View SEC Filing  
2/9/2015David FarberMajor ShareholderSell2,500$55.00$137,500.00View SEC Filing  
2/9/2015Kevin SmithVPSell53,534$55.36$2,963,642.24View SEC Filing  
2/6/2015G. Michael LandisInsiderSell12,049$52.93$637,753.57View SEC Filing  
1/26/2015David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
1/15/2015Arthur P BedrosianCEOSell5,000$43.50$217,500.00View SEC Filing  
12/15/2014Arthur P BedrosianCEOSell5,000$43.81$219,050.00View SEC Filing  
12/10/2014Martin P GalvanCFOBuy1,000$42.40$42,400.00View SEC Filing  
12/8/2014Ernest SaboVPSell6,000$48.03$288,180.00View SEC Filing  
10/27/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
9/16/2014Arthur P BedrosianCEOSell5,000$40.05$200,250.00View SEC Filing  
8/18/2014David FarberMajor ShareholderSell5,000$41.30$206,500.00View SEC Filing  
7/15/2014Arthur P BedrosianCEOSell5,000$47.19$235,950.00View SEC Filing  
6/23/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
6/16/2014Arthur P BedrosianCEOSell5,000$46.96$234,800.00View SEC Filing  
6/16/2014David FarberMajor ShareholderSell10,000$43.53$435,300.00View SEC Filing  
6/16/2014Paul TaveiraDirectorSell1,000$46.94$46,940.00View SEC Filing  
3/17/2014William SchreckCOOSell16,600$43.85$727,910.00View SEC Filing  
3/12/2014William SchreckCOOSell55,563$43.31$2,406,433.53View SEC Filing  
2/20/2014Kevin SmithVPSell64,665$45.11$2,917,038.15View SEC Filing  
2/13/2014Kevin SmithVPSell20,000$40.48$809,600.00View SEC Filing  
12/13/2013Arthur BedrosianCEOBuy5,000$27.85$139,250.00View SEC Filing  
12/13/2013Martin GalvanCFOBuy3,000$26.90$80,700.00View SEC Filing  
5/14/2013Kevin SmithVPSell24,984$11.86$296,310.24View SEC Filing  
5/13/2013Kevin SmithVPSell41,929$11.80$494,762.20View SEC Filing  
5/10/2013Ernest SaboVPSell15,000$11.29$169,350.00View SEC Filing  
3/14/2013Paul TaveiraDirectorBuy1,000$9.73$9,730.00View SEC Filing  
2/13/2013Martin P GalvanCFOBuy4,000$6.88$27,520.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Lannett (NYSE:LCI)
DateHeadline logoEPS Target Range For Lannett Co Inc (NYSE:LCI) At $2.85 – $3.48 - (NYSE:LCI) - October 24 at 11:11 AM logoYearly EPS Estimate Of Lannett Co Inc (NYSE:LCI) At $3.22 | Stocks ... - Stocks Daily (NYSE:LCI) - October 24 at 11:11 AM logoYearly EPS Estimate Of Lannett Co Inc (NYSE:LCI) At $3.22 (NYSE:LCI) - October 23 at 5:43 PM logoGeneric drug makers scrambling to preserve marketing approvals of generic versions of J&J's ADHD med Concerta (NYSE:LCI) - October 23 at 10:15 AM
News IconNationwide Fund Advisors Increases Position in Lannett Co. (LCI ... - DailyQuint (NYSE:LCI) - October 22 at 5:34 PM
News Icon2 Stocks Attracting Analyst Attention: Clovis Oncology, Inc. (NASDAQ:CLVS), Lannett Company, Inc. (NYSE:LCI) - The Voice Registrar (NYSE:LCI) - October 21 at 5:56 PM
News IconDeutsche Bank AG Reiterates “Hold” Rating for Lannett Co. (LCI ... - DailyQuint (NYSE:LCI) - October 21 at 5:56 PM logoLANNETT CO INC Files SEC form 8-K, Material Impairments, Other Events (NYSE:LCI) - October 21 at 5:56 PM
News IconAnalysts Valuations For Two Stocks: Lannett Company, Inc. (NYSE:LCI), Lattice Semiconductor Corporation (NASDAQ ... - The Voice Registrar (NYSE:LCI) - October 20 at 11:35 AM logoLannett: FDA To Withdraw Approval Of ANDA For Methylphenidate ER Tablets (NYSE:LCI) - October 19 at 6:14 PM logoLannett (LCI) Receives FDA Notice of Intention to Withdraw Methylphenidate HCl ER Tablets ANDA; Offers Commentary (NYSE:LCI) - October 19 at 6:14 PM logoFDA to withdraw approval of Lannett's generic ADHD drug (NYSE:LCI) - October 19 at 6:14 PM logoWhy Lannett Company, Inc. Shares Got Pummeled Today - Motley Fool (NYSE:LCI) - October 19 at 10:51 AM logoLannett Comments On FDA Proposal Regarding Methylphenidate Extended Release Tablets (NYSE:LCI) - October 19 at 10:51 AM logoMallinckrodt (MNK), Lannett (LCI) Price Targets Lowered at Deutsche Bank After FDA Proposes to Withdraw ANDAs for Methylphenidate ER (NYSE:LCI) - October 17 at 5:49 PM logoWhy Lannett Company, Inc. Shares Got Pummeled Today (NYSE:LCI) - October 17 at 4:57 PM
News IconBroker Roundup For Lannett Co Inc (NYSE:LCI) - The De Soto Edge - The De Soto Edge (NYSE:LCI) - October 16 at 10:21 AM
News IconShare Value Diminishing Over Past Month: Lannett Company, Inc. (NYSE:LCI) - CSZ News (NYSE:LCI) - October 15 at 5:35 PM
News IconWill Lannett Company, Inc. (NYSE:LCI) beat earning estimates again? - The Independent Republic (NYSE:LCI) - October 15 at 5:35 PM
News IconOwnership Don't Lie: Lannett Co Inc (NYSE:LCI) Quarterly Sentiment Report - Post News (NYSE:LCI) - October 13 at 9:25 AM logoETF’s with exposure to Lannett Co., Inc. : October 12, 2016 (NYSE:LCI) - October 12 at 11:05 AM
News IconStocks in Volatile Measures: Mast Therapeutics, Inc. (NYSE:MSTX), Lannett Company, Inc. (NYSE:LCI) - Street Wise Report (press release) (blog) (NYSE:LCI) - October 10 at 5:36 PM logoLannett Co Inc (NYSE:LCI) Mean Price Target At $41 - (NYSE:LCI) - October 10 at 5:36 PM
News IconLannett Company, Inc. (NYSE:LCI) Earnings Preview: Should Investors Be Nervous? - The Voice Registrar (NYSE:LCI) - October 6 at 5:45 PM logoLannett Co Inc Common Stock (LCI) Investment Increased by Telemus Capital, LLC (NYSE:LCI) - October 5 at 5:48 PM
News IconBroker Roundup For Lannett Co Inc (NYSE:LCI) - The De Soto Edge (NYSE:LCI) - October 4 at 5:44 PM logoLannett Co Inc (NYSE:LCI) Mean Price Target At $41 (NYSE:LCI) - October 2 at 5:12 PM logoCommit To Buy Lannett At $17.50, Earn 9.4% Using Options (NYSE:LCI) - September 27 at 5:49 PM logoETF’s with exposure to Lannett Co., Inc. : September 27, 2016 (NYSE:LCI) - September 27 at 10:30 AM logoLannett scientific chief bids adieu; shares ease 5% (NYSE:LCI) - September 23 at 5:34 PM logoStocks Alert - Valeant Pharmaceuticals, (NYSE:VRX), Lannett Company, (NYSE:LCI), Godaddy, (NYSE:GDDY) - Wall Street 24 (NYSE:LCI) - September 23 at 10:37 AM logoLannett Co., Inc. breached its 50 day moving average in a Bearish Manner : LCI-US : September 23, 2016 (NYSE:LCI) - September 23 at 10:37 AM logoLannett scientific chief bids adieu; shares ease 5% - Seeking Alpha (NYSE:LCI) - September 22 at 5:41 PM
News IconLannett Co. (LCI) Trading Down 4.6% - NewsDen (NYSE:LCI) - September 22 at 5:41 PM logoLANNETT CO INC Files SEC form 8-K, Change in Directors or Principal Officers (NYSE:LCI) - September 22 at 5:41 PM logoLannett (LCI) Chief of Scientific Affairs Mahendra Dedhiya Resigns (NYSE:LCI) - September 22 at 9:05 AM logoLannett Announces Resignation Of Mahendra Dedhiya, Ph.D., Chief Of Scientific Affairs (NYSE:LCI) - September 22 at 9:05 AM logoFDA approves Lannett's Buprenorphine and Naloxone sublingual tablets (NYSE:LCI) - September 21 at 10:02 AM logoStock is down at $32.48 (LCI) Lannett Announces Approval For… (NYSE:LCI) - September 21 at 10:02 AM logoLannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg (NYSE:LCI) - September 20 at 11:02 AM
News IconStocks Hammered on Sluggish Data: CVS Health Corporation (NYSE:CVS), Lannett Company, Inc. (NYSE:LCI) - Street Wise Report (press release) (blog) (NYSE:LCI) - September 19 at 5:54 PM
News IconWhat are Analysts Expecting for Lannett Co Inc (NYSE:LCI) Earnings? - Frisco Fastball (NYSE:LCI) - September 19 at 5:54 PM logoLannett (LCI) Announces FDA Completes Successful Inspections of ... - (NYSE:LCI) - September 19 at 10:26 AM logo6:55 am Lannett announces successful FDA inspections of facilities (NYSE:LCI) - September 19 at 10:26 AM logoLannett Announces Successful FDA Inspections of Three Facilities (NYSE:LCI) - September 19 at 10:26 AM
News IconAnalyst Projections and Growth Recap for Lannett Company, Inc ... - Post News (NYSE:LCI) - September 15 at 3:52 PM logoLannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : September 13, 2016 (NYSE:LCI) - September 13 at 10:43 AM logoLannett Co Inc (NYSE:LCI): The Buzzing Stock (NYSE:LCI) - September 10 at 5:24 PM logoLannett Co Inc (NYSE:LCI): The Buzzing Stock | Stocks Daily - Stocks Daily (NYSE:LCI) - September 10 at 10:15 AM logoAn Updated Lannett Valuation - Hillary Clinton Edition (NYSE:LCI) - September 6 at 5:54 PM


Lannett (NYSE:LCI) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff